- >>> Experimental Medicine December 2010 issue
- >>> Experimental Medicine February 2011 issue
Special Interview： The Quest for Drugs Targeting Sirtuins
David A. Sinclair, Ph.D.
The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Department of Pathology, Harvard Medical School
David A. Sinclair, Ph.D.
- The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Department of Pathology, Harvard Medical School
In 2003, Dr. Sinclair published a landmark paper demonstrating that resveratrol extends the lifespan of yeast (Nature, 425: 191-196, 2003). Based on this discovery, he and his colleagues founded a biotechnology venture company, Sirtris Pharmaceuticals, in 2004. He has been investigating sirtuin-targeting small chemical compounds that boost the body’s natural defenses against diseases of aging. In this interview, Dr. Sinclair talks about his vision of the future of aging research and drug discovery targeting sirtuins.
Interviewer：Shuji Hachisuka(Editor of Experimental Medicine, Yodosha,co., Ltd.) , Chihiro Sato, Ph.D. (Washington University School of Medicine)
Streaming Video Clips
HTML5 Version (for iPad/iPhone)
![[DIGEST]](/jikkenigaku/images/washu_digest.gif)
The Quest for Drugs Targeting Sirtuins- David A. Sinclair, Ph.D.
- 4:25 [November 22nd, 2010]
![[1]](/jikkenigaku/images/washu_number_1.gif)
The discovery of STACs (SIRT1 activating compounds) and the foundation of Sirtirs Pharmaceuticals- David A. Sinclair, Ph.D.
- 8:11 [November 22nd, 2010]
- The fascination to aging research［2:33］／Episodes to found Sirtris Pharmaceuticals［3:21］／Current perspectives on SIRT1 activators［1:37］
![[2]](/jikkenigaku/images/washu_number_2.gif)
Can sirtuins extend human's lifespan and healthspan?- David A. Sinclair, Ph.D.
- 8:50 [November 30th, 2010]
- Recent advances in mitochondrial sirtuins［2:02］／Can we regulate aging by sirtuins? ［2:39］／Messages for young scientists［2:30］
